Young leader steers 50-year-old pharmaceutical company, Jiangxi Biological (06915.HK) enters a new growth trajectory
$JIANGXI BIO(06915.HK) The process of listing in Hong Kong is in full swing. As the largest provider of human tetanus antitoxin (TAT) in China and globally, this company is attracting the attention of many investors with its robust operational foundation and clear commercialization blueprint.
The unique management combination of "young helmsman + established corporate foundation" is another distinctive core label for Jiangxi Biological, in addition to its rare advantage of full industry chain integration. The company's chairwoman, Ms. Jing Yue, is only 33 years old and possesses international management reserve capabilities and strategic vision, injecting modern management concepts and strategic foresight into this established company whose history can be traced back to 1969. The senior expert team led by General Manager Mr. Yao Xiaodong forms the company's solid technical and operational foundation. The dual guarantee of "innovation + experience" not only supports the company's stable governance and internal control during global expansion, but also gives the enterprise the courage to explore new avenues and the confidence to maintain its quality lifeline.
As mentioned earlier, one of Jiangxi Biological's core competitive advantages stems from its decades-long accumulation in building a full industry chain. From upstream horse breeding and plasma collection, to midstream antigen development and animal immunization, to downstream purification and formulation, and global sales, the company has achieved end-to-end independent control. Its horse base in Gansu is the largest GMP-level facility in China, and its production base in Ji’an, Jiangxi, is the first domestic base to adopt isolator aseptic filling technology.
This integrated capability spanning the entire value chain provides solid production capacity and quality assurance for the rapid commercialization of Jiangxi Biological's "human + veterinary" dual-wheel pipeline. This is also a capability possessed by only a few anti-serum companies globally; in China alone, there are only three, and Jiangxi Biological is the largest in scale.
Currently, this capability has extended into strategic depth at the platform level for anti-serum technology. Jiangxi Biological is the only company in the world using recombinant protein, mRNA, and serum-free antigen technologies to develop anti-serum products, and it is also the first and only company in China to adopt preservative-free packaging and pasteurization virus removal/inactivation technology for human-use TAT. These breakthroughs have significantly improved the purity and safety of existing products; they also demonstrate the company's pipeline migration capability of its anti-serum platform technology, laying a solid technical foundation for future exploration in toxin neutralization, immunity, and anti-infection prevention in areas such as human and veterinary medicine.
This Hong Kong IPO clearly outlines Jiangxi Biological's strategic blueprint for leaping from a single leader to a comprehensive biopharmaceutical platform through its fundraising purposes. In terms of commercialization progress, the company's self-developed veterinary TAT and pregnant mare serum gonadotropin (PMSG) are expected to be launched successively from June to July 2026, potentially becoming new revenue growth points. Meanwhile, the chicken bursal disease injection introduced through cooperative licensing is expected to obtain registration certificates in July 2026, porcine spleen transfer factor is expected to start commercialization in Q4 2026, and recombinant porcine interferon alpha (rPoIFN-α) is also planned to submit a new veterinary drug application in September this year. With the batch launch of veterinary products, the company's "human + veterinary" dual-wheel matrix will not only optimize its revenue structure but also inject a new growth anchor into its valuation framework.
Overall, with its robust internal control and governance, full industry chain capability, and highly promising anti-serum pipeline, Jiangxi Biological has built a clear growth ladder. Guided by its "established foundation" and "young vision," the company has steadily entered a new track of long-term growth, and its commercialization path and dual-engine valuation anchor deserve continued close attention.
(Written by: Li Huifen, Chairwoman of the Greater Bay Area Family Office Association)(The author does not hold the above-mentioned stocks)
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
